BLLN trades 19.0% below Wall Street's consensus target of $126.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BLLN achieves its forward estimates and maintains a stable P/E multiple of 133.3x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, BillionToOne, Inc. (BLLN) has a Wall Street consensus price target of $126.00, based on estimates from 4 covering analysts. With the stock currently trading at $105.90, this represents a potential upside of +19.0%. The company has a market capitalization of $4.87B.
Analyst price targets range from a low of $120.00 to a high of $130.00, representing a 8% spread in expectations. The median target of $128.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BLLN trades at a trailing P/E of 1662.5x and forward P/E of 133.3x. Analysts expect EPS to grow +29.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NTRANatera, Inc. | $58.8B | $410.35 | $350.07 | -14.7% | Buy | — | 28 |
 ILMNIllumina, Inc. | $41.3B | $273.04 | $237.00 | -13.2% | Buy | 51.0x | 50 |
 PGNYProgyny, Inc. | $2.0B | $25.23 | $35.50 | +40.7% | Buy | 19.6x | 20 |
 CDNACareDx, Inc | $3.5B | $67.15 | $62.25 | -7.3% | Buy | 56.1x | 13 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 PACBPacific Biosciences of California, Inc. | $789M | $2.54 | $1.18 | -53.5% | Buy | — | 18 |
 PRMEPrime Medicine, Inc. | $538M | $2.98 | $7.50 | +151.7% | Buy | — | 10 |
 TMOThermo Fisher Scientific Inc. | $243.3B | $654.80 | $631.42 | -3.6% | Buy | 26.1x | 43 |
 DHRDanaher Corporation | $150.5B | $214.06 | $227.62 | +6.3% | Buy | 25.2x | 43 |
 AAgilent Technologies, Inc. | $47.4B | $167.77 | $170.00 | +1.3% | Buy | 27.1x | 41 |
Quick answers to the most common questions about buying BLLN stock.
BillionToOne, Inc. (BLLN) has a consensus 12-month price target of $126, implying 19.0% upside from $105.9. The 4 analysts covering BLLN see moderate appreciation potential.
BLLN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $126 implies 19.0% upside from current levels.
At a forward P/E of 133.3249x, BLLN trades at a premium valuation. The consensus price target of $126 (19.0% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $130 for BLLN, while the most conservative target is $120. The consensus of $126 represents the median expectation. These targets typically reflect 12-month expectations.
BLLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BLLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $126, with estimates ranging from $120 (bear case) to $130 (bull case). The median consensus rating is "Buy".
BLLN trades at a forward P/E ratio of 133.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 1662.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on BLLN, with a "Buy" consensus rating and $126 price target (19.0% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BLLN analyst price targets range from $120 to $130, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $126 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.